Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the company's shares to fall nearly 5 percent in early trading Wednesday. (BioWorld Today)

Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the company's shares to fall nearly 5 percent in early trading Wednesday. (BioWorld Today)

KAI Pharmaceuticals Inc. signed a potential $340 million deal expected to be announced today with Daiichi Sankyo Co. Ltd. for the global development and commercialization of KAI-9803. (BioWorld Today)

KAI Pharmaceuticals Inc. signed a potential $340 million deal expected to be announced today with Daiichi Sankyo Co. Ltd. for the global development and commercialization of KAI-9803. (BioWorld Today)